# BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

> **NCT01830127** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 35 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Ribavirin
- **DRUG:** BI 207127 high dose
- **DRUG:** Faldaprevir
- **DRUG:** Ribavirin
- **DRUG:** BI 207127 low dose
- **DRUG:** Faldaprevir

## Key facts

- **NCT ID:** NCT01830127
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2015-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01830127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01830127, "BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01830127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*